Modulation of fiaf and the gastrointestinal microbiota as a means to control energy storage in a subject

• US 20050239706A1
• Filed: 03/15/2005
• Published: 10/27/2005
• Est. Priority Date: 10/31/2003
• Status: Abandoned Application

• Current Assignee: Washington University In St Louis
• Original Assignee: Washington University In St Louis
• Inventors: Hooper, Lora V., Rawls, John, Sonnenburg, Justin, Backhed, Fredrik, Gordon, Jeffrey I.
• Application Number:
  US11/080,755
• Publication Number:
  US 20050239706A1
• Time in Patent Office: Days
• US Class Current: 514/4.800
• CPC Class Codes: A61K 35/741 Probiotics probiotic yeast, e.g. saccharomyces A61K36/06
• CPC Class Codes: A61K 38/1709 from mammals
• CPC Class Codes: A61P 3/04 Anorexiants; Antiobesity agents
• CPC Class Codes: A61P 3/06 Antihyperlipidemics

Abstract

The invention provides compositions and methods to modulate fat storage and weight loss in a subject. In certain aspects of the invention, fat storage (adiposity) and weight loss is modulated by altering the subject'"'"'s gastrointestinal microbiota population. In other aspects of the invention, fat storage and weight loss is modulated by altering the amount of or the activity of the protein, fasting-induced adipocyte factor, in the subject.

Claims

1. A method for treating obesity or an obesity-related disorder, the method comprising:

(a) diagnosing a subject in need of treatment for obesity or an obesity-related disorder; and

(b) increasing either the amount of or the activity of a Fiaf polypeptide in the subject.

2. The method of claim 1, wherein the amount of Fiaf polypeptide is increased in the subject by administering an effective amount of Fiaf polypeptide to the subject.

3. The method of claim 2, wherein the subject is selected from the group consisting of a human, a dog, a cat, a cow, a horse, a rabbit, a pig, a sheep, a goat, an avian species and a fish species.

4. The method of claim 3, wherein the obesity related disorder is selected from the group consisting of metabolic syndrome, type II diabetes, hypertension, cardiovascular disease, and nonalcoholic fatty liver disease.

5. The method of claim 4, wherein the amount of or the activity of the Fiaf polypeptide is increased by administering a PPAR agonist to the subject.

6. A method for decreasing body fat or for promoting weight loss in a subject, the method comprising increasing either the amount of or the activity of a Fiaf polypeptide in the subject.

7. The method of claim 6, wherein the amount of Fiaf polypeptide is increased in the subject by administering an effective amount of a Fiaf polypeptide to the subject.

8. The method of claim 7, wherein the subject is selected from the group consisting of a human, a dog, a cat, a cow, a horse, a rabbit, a pig, a sheep, a goat, an avian species and a fish species.

9. The method of claim 8, wherein the amount of or the activity of the Fiaf polypeptide is increased by administering a PPAR agonist to the subject.

10. A method for decreasing body fat or for promoting weight loss in a subject, the method comprising altering the microbiota population in the subject'"'"'s gastrointestinal tract such that at least one microbial-mediated signaling pathway in the subject that regulates energy storage is either stimulated or substantially inhibited, whereby stimulating or inhibiting the signaling pathway causes a decrease in body fat or promotes weight loss in the subject.

11. The method of claim 10, wherein the microbiota population is altered by decreasing the presence of at least one genera of saccharolytic microbe.

12. The method of claim 10, wherein the microbiota population is altered by decreasing the presence of B. thetaiotaomicron.

13. The method of claim 11, wherein the presence of a microbe genera is decreased by administering a probiotic selected from the group consisting of Lactobacillus, Acidophilus, Bifidobacteria and other components of the gut microbiota.

14. The method of claim 10, wherein the signaling pathway regulates hepatic lipogenesis and is substantially inhibited, thereby resulting in a decrease of triglyceride storage in the adipocytes of the subject.

15. The method of claim 14, wherein the amount of at least one compound selected from the group consisting of acetyl-CoA carboxylase, fatty acid synthase, sterol response element binding protein 1 and carbohydrate response element binding protein is decreased in the subject.

16. The method of claim 14, wherein hepatic lipogenesis is substantially inhibited as a result of a decrease in microbial processing of dietary polysaccharides.

17. The method of claim 14, wherein the signaling pathway substantially decreases lipoprotein lipase activity and results in a decrease of triglyceride storage in the adipocytes of the subject.

18. The method of claim 17, wherein lipoprotein lipase activity is substantially decreased as a result of microbial-mediated transcriptional suppression of a Fiaf polypeptide.

19. The method of claim 18, wherein microbial-mediated transcriptional suppression of the Fiaf polypeptide occurs only in the gastrointestinal tract of the subject.

20. The method of claim 10, wherein the subject is selected from the group consisting of a human, a dog, a cat, a cow, a horse, a rabbit, a pig, a sheep, a goat, an avian species and a fish species.

21. The method of claim 10, further comprising administering to the subject an effective amount of a Fiaf polypeptide.

22. A method for decreasing body fat or for promoting weight loss in a subject, the method comprising altering the microbiota population in the subject'"'"'s gastrointestinal tract such that microbial-mediated transcriptional suppression of a lipoprotein lipase inhibitor in the subject is decreased.

23. The method of claim 22, wherein the lipoprotein lipase inhibitor is a Fiaf polypeptide.

24. The method of claim 23, wherein microbial-mediated transcriptional suppression of the Fiaf polypeptide occurs only in the gastrointestinal tract of the subject.

25. The method of claim 22, wherein the microbiota population is altered by decreasing the presence of at least one genera of saccharolytic microbe.

26. The method of claim 22, wherein the microbiota population is altered by decreasing the presence of B. thetaiotaomicron.

27. The method of claim 25, wherein the presence of a microbe is decreased by administering a probiotic selected from the group consisting of Lactobacillus, Acidophilus, Bifidobacteria and other components of the gut microbiota.

28. The method of claim 22, wherein the subject is selected from the group consisting of a human, a dog, a cat, a cow, a horse, a rabbit, a pig, a sheep, a goat, an avian species and a fish species.

29. The method of claim 22, further comprising administering to the subject an effective amount of a Fiaf polypeptide.

30. A method for treating obesity or an obesity-related disorder, the method comprising:

(a) diagnosing a subject in need of treatment for obesity or an obesity-related disorder; and

(b) altering the microbiota population in the subject'"'"'s gastrointestinal tract such that microbial-mediated transcriptional suppression of a lipoprotein lipase inhibitor in the subject is decreased.

31. The method of claim 30, wherein the lipoprotein lipase inhibitor is a Fiaf polypeptide.

32. The method of claim 31, wherein microbial-mediated transcriptional suppression of the Fiaf polypeptide occurs only in the gastrointestinal tract of the subject.

33. The method of claim 30, wherein the microbiota population is altered by decreasing the presence of at least one genera of saccharolytic microbe.

34. The method of claim 30, wherein the microbiota population is altered by decreasing the presence of B. thetaiotaomicron.

35. The method of claim 33, wherein the presence of a microbe genera is decreased by administering a probiotic selected from the group consisting of Lactobacillus, Acidophilus, Bifidobacteria and other components of the gut microbiota.

36. The method of claim 30, wherein the subject is selected from the group consisting of a human, a dog, a cat, a cow, a horse, a rabbit, a pig, a sheep, a goat, an avian species and a fish species.

37. The method of claim 30, wherein the obesity related disorder is selected from the group consisting of metabolic syndrome, type II diabetes, hypertension, cardiovascular disease, and nonalcoholic fatty liver disease.

38. The method of claim 30, further comprising administering to the subject an effective amount of a Fiaf polypeptide.

39. A composition for decreasing body fat or for promoting weight loss, the composition comprising a Fiaf polypeptide and an agent that alters the microbiota population in a subject'"'"'s gastrointestinal tract such that microbial-mediated transcriptional suppression of a lipoprotein lipase inhibitor in the subject is decreased.

40. The composition of claim 39, wherein the agent is a probiotic selected from the group consisting of Lactobacillus, Acidophilus, Bifidobacteria and other components of the gut microbiota.

41. The composition of claim 39, wherein the composition further comprises a compound selected from the group consisting of acarbose, Xenical, orlistat, an amphetamine and sibutramine.

42. A biomarker for use in predicting whether a subject is at risk for becoming obese or suffering from an obesity-related condition, the biomarker comprising the amount of circulating Fiaf polypeptide.